TD Asset Management Inc Purchases 138,588 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

TD Asset Management Inc grew its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 384.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 174,674 shares of the company’s stock after acquiring an additional 138,588 shares during the period. TD Asset Management Inc owned 0.29% of Structure Therapeutics worth $12,149,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Ameriprise Financial Inc. lifted its stake in shares of Structure Therapeutics by 7.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after acquiring an additional 106,389 shares during the last quarter. Casdin Capital LLC lifted its stake in shares of Structure Therapeutics by 26.9% in the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after acquiring an additional 330,000 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Structure Therapeutics by 63.1% in the 4th quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock valued at $89,317,000 after acquiring an additional 496,726 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Structure Therapeutics by 4.5% in the 3rd quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its stake in shares of Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after acquiring an additional 397,272 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Stock Up 0.5%

Shares of NASDAQ:GPCR opened at $37.77 on Tuesday. The firm has a market cap of $2.68 billion, a P/E ratio of -43.41 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90. The business has a fifty day simple moving average of $44.03 and a 200 day simple moving average of $57.13.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. BMO Capital Markets set a $145.00 target price on Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. HC Wainwright lowered their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 16th. Citizens Jmp lowered their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $109.25.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.